ClinicalTrials.gg
Not yet recruitingNCT07380659Updated Feb 2, 2026

Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock

A Phase 1 interventional study of FAP allogeneic immunosuppressive CAR-DC in Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction and STEMI - ST Elevation Myocardial Infarction, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Shock, Cardiogenic with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Shock, Cardiogenic · China.

Planned enrollment
14th of 14
18 · median 82
Started
2026
with 3 others
Phase 1
Only one
of the 20
Primary completion
2027-01
later than 11 of 17 live
Registered
18th of 20
by date

Among the 20 studies in Shock, Cardiogenic with a site in China, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 1, reaches primary completion later than 11 of the 17 other live ones, and was the 18th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

18 of the 20 studies in Shock, Cardiogenic with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Shock, Cardiogenic with a site in China, or all of them as a file.
02

Study summary

To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.

Read the detailed description

Background: Cardiogenic shock following acute myocardial infarction (AMI) remains a major unresolved clinical challenge. Despite advances in urgent revascularization and mechanical circulatory support, short-term mortality remains unacceptably high, approaching 40% within 30 days. Few evidence-based therapies have demonstrated a meaningful survival benefit, highlighting the urgent need for novel, mechanism-driven interventions. Growing clinical and experimental evidence indicates that a dysregulated systemic inflammatory response-manifested by hyperthermia, leukocytosis, and elevated proinflammatory mediators-plays a central role in the pathophysiology and progression of cardiogenic shock. Excessive inflammation exacerbates myocardial dysfunction, promotes multiorgan injury, and impairs recovery, suggesting that targeted immunomodulation may represent a complementary therapeutic strategy in this high-risk population. Dendritic cells (DCs), as professional antigen-presenting cells, occupy a pivotal position at the interface of innate and adaptive immunity and are uniquely suited to orchestrate context-dependent immune responses. In particular, tolerogenic DCs exert potent immunosuppressive effects through regulatory cytokine production, expression of co-inhibitory ligands, antigen-specific suppression of effector T cells, and induction of regulatory T cells. Collectively, these properties render DCs an attractive yet underexplored cellular platform for resolving excessive inflammation and promoting tissue repair in cardiogenic shock with AMI.

Purpose: In this prospective clinical study, the investigators engineered a stable, immunosuppressive, and fibrotic lesion-targeted DC therapy, termed immunosuppressive DCs (iCDC). This study was designed to evaluate the safety and preliminary efficacy of allogeneic fibroblast activation protein (FAP)-targeted iCDC therapy in patients with AMI complicated by cardiogenic shock.

Study design: This single-center, prospective, concurrent non-randomized controlled clinical trial enrolls patients aged 18-80 years presenting with acute myocardial infarction complicated by cardiogenic shock. Eligible patients are treated with allogeneic FAP-targeted immunosuppressive iCDC therapy.

Outcome measure: The primary outcome is the safety of FAP-targeted immunosuppressive iCDC therapy in patients with AMI complicated by cardiogenic shock. Secondary outcomes include 30-day all-cause mortality; hemodynamic parameters following iCDC therapy (systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate); time to hemodynamic stabilization; dose and duration of vasopressor and inotropic support; arterial lactate levels; changes in biomarkers (BNP, CRP, creatinine, ALT, AST, and inflammatory mediators); need for and duration of mechanical ventilation; need for and duration of left ventricular assist device implantation; intensive care unit and total hospital length of stay; left ventricular ejection fraction assessed by echocardiography; SAPS II score; SCAI shock classification; heart failure symptom burden assessed by NYHA functional class and the Kansas City Cardiomyopathy Questionnaire; incidence of major adverse cardiovascular events (MACE), including cardiac death and heart failure hospitalization; and incidence of adverse events.

03

Conditions studied

  • Cardiogenic Shock
  • Cardiogenic Shock Post Myocardial Infarction
  • STEMI - ST Elevation Myocardial Infarction

Keywords

  • acute myocardial infarction with cardiogenic shock
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria(patients):

  • Age ≥ 18 years and \< 80 years.
  • Acute ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock, meeting all the following conditions:

    1. Post-emergent revascularization (PCI or CABG)
    2. Systolic blood pressure \< 90 mmHg for >30 minutes, or requiring catecholamine support to maintain systolic blood pressure >90 mmHg
    3. Signs of impaired organ perfusion, meeting at least one of the following criteria:

      1. Altered mental status
      2. Cold, clammy skin and extremities
      3. Oliguria, with urine output \<30 mL/h
      4. Arterial lactate level >2 mmol/L
  • The patient or their legally authorized representative is capable of providing verbal confirmation of understanding the trial risks, benefits, and treatment alternatives associated with receiving CAR-DC therapy, and provides written prior to participation in this clinical trial.

Exclusion Criteria(patients):

  1. Acute mechanical complications of infarction (e.g., ventricular septal rupture, acute mitral regurgitation).
  2. Cardiac arrest.
  3. Hypoxic-ischemic brain injury (cerebral injury with fixed and dilated pupils not attributable to medication).
  4. Shock due to other causes (e.g., sepsis, hypovolemia).
  5. Resuscitation duration >30 minutes.
  6. Absence of spontaneous cardiac activity.
  7. Persistent electrical instability.
  8. Active bleeding or to heparin use.
  9. Active disease requiring immunosuppressive therapy.
  10. History of .
  11. Infection, including:

    • Active (HBV DNA >1000 copies/mL by PCR), , syphilis, or infection at screening.
    • Uncontrolled systemic fungal, bacterial, viral, or other pathogen infections.
  12. Pregnant women.
  13. Contraindications to the drug or study procedures.

Inclusion Criteria(donors):

  • Age ≥ 18 years and ≤ 75 years.
  • Has provided written informed consent.
  • Hematocrit >30%, lymphocyte count >0.5 × 10\^9/L, count >60 × 10\^9/L.
  • Pathogen screening results must be negative for HIV (antigen, core antibody, and RNA), HBV (surface antigen and core antibody), HCV, syphilis, CMV, and EBV.

Exclusion Criteria(donors):

  • Active infection requiring treatment.
  • History of malignancy.
  • Active autoimmune disease requiring immunosuppressive therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Administration of allogeneic FAP iCDC

    Administration of FAP immunosuppressive CAR-DC cell therapy in AMI CS. Patients are planned to be enrolled in the dose-escalation trial (1×10\^5/kg、4×10\^5/kg、and 8×10\^5/kg) .The first dose group (4×10⁵/kg) initially enrolls 3 subjects to observe Dose-Limiting Toxicity (DLT) responses. 1. If no DLT occurs and all 3 subjects demonstrate efficacy after 6 months of treatment, and this dose is determined as the safe and effective dose. 2. If 1 subject experiences DLT, 3 additional subjects are enrolled. ·If 1/6 subjects develops DLT, and efficacy is not fully achieved in all 6 subjects, escalate to the next dose group (8×10\^5/kg). ·If ≥2/6 subjects develop DLT, de-escalate to the previous dose group (1×10\^5/kg). 3. After identifying a safe and effective dose, enrollment will be expanded at this dose to bring the total sample size to 8-10 subjects, to further evaluate safety and efficacy.

    Biological: FAP allogeneic immunosuppressive CAR-DC

  • No intervention
    Standard therapy

    Patients in the control group do not receive cellular therapy intervention.

Interventions

  • BiologicalFAP allogeneic immunosuppressive CAR-DC

    Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion at the first day of shock.

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with Dose-limiting toxicity (DLT)

    The proportion of participants with DLT as assessed by CTCAE v5.0

    Time frame: in 14 days after injection

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of iCDC treatment-emergent adverse events

    Time frame: in 14 days after injection

Secondary outcomes

  1. All-cause mortality

    All-cause mortality at 30 days after iCDC treatment

    Time frame: 30 days after injection

  2. Systolic blood pressure

    Systolic blood pressure (mmHg) measured using a calibrated sphygmomanometer under standardized conditions.

    Time frame: 24 hours、48 hours、72 hours、7 days after injection

  3. Diastolic blood pressure

    Diastolic blood pressure (mmHg) measured using a calibrated sphygmomanometer under standardized conditions.

    Time frame: 24 hours、48 hours、72 hours、7 days after injection

  4. Mean arterial pressure

    The mean arterial pressure (MAP) is calculated using the following formula: MAP=DBP+1/3(SBP-DBP);DBP : Diastolic blood pressure,SBP :Systolic blood pressure

    Time frame: 24 hours、48 hours、72 hours、7 days after injection

  5. Time to hemodynamic stability

    Sustained (\> 60 min) systolic blood pressure \>90 mmHg without requirement for catecholamines and without signs of peripheral endorgan hypoperfusion

    Time frame: From the end of the iCDC infusion to achievement of hemodynamic stability, assessed continuously until ICU discharge (up to 30 days).

  6. Dose of vasopressors

    Dose of vasopressors administered to the participant.

    Time frame: 24 hours、48 hours、72 hours、7 days after injection

  7. Duration of vasopressor use

    Duration of vasopressor therapy in days treated with vasopressor between enrollment and hospital discharge. A day treated with vasopressor is any day during the hospital period where the patient received a vasopressor.

    Time frame: From enrollment to hospital discharge (up to 30 days).

  8. Dose of inotropic drugs

    Dose of inotropic drugs administered to the participant.

    Time frame: 24 hours、48 hours、72 hours、7 days after injection

  9. Duration of inotropic drugs use

    Duration of inotropic drugs therapy in days treated with inotropic drugs between enrollment and hospital discharge. A day treated with inotropic drugs is any day during the hospital period where the patient received inotropic drugs

    Time frame: From enrollment to hospital discharge (up to 30 days).

  10. Serum lactate level

    Lactate is assessed via arterial blood gas analysis.

    Time frame: The measurement frequency is once every 8 hours for a duration of 48 hours.

  11. Change in B-type natriuretic peptide (BNP) level from baseline

    Change in serum B-type natriuretic peptide concentration compared with baseline.

    Time frame: 7 days,14 days,30 days after injection.

  12. Change in C-reactive protein (CRP) level from baseline

    Change in serum C-reactive protein concentration compared with baseline.

    Time frame: 24 hours, 72 hours, 7 days,14 days after injection.

  13. Change in serum creatinine level from baseline

    Change in serum creatinine concentration compared with baseline.

    Time frame: 24 hours, 72 hours, 7 days,14 days after injection.

  14. Change in ALT (Alanine Aminotransferase) level from baseline

    Change in serum ALT concentration compared with baseline.

    Time frame: 24 hours, 72 hours, 7 days,14 days after injection.

  15. Change in AST (Aspartate Aminotransferase) level from baseline

    Change in serum AST concentration compared with baseline.

    Time frame: 24 hours, 72 hours, 7 days,14 days after injection.

  16. Change in Interleukin-6 (IL-6) levels from baseline

    Change in serum Interleukin-6 (IL-6) levels compared with baseline.

    Time frame: 24 hours, 72 hours, 7 days,14 days after injection.

  17. Need for mechanical ventilation

    Need for mechanical ventilation is defined as requiring invasive or non-invasive positive pressure ventilation for at least 1 hour due to respiratory failure.

    Time frame: From the end of the drug infusion until ICU discharge (up to 30 days).

  18. Duration of mechanical ventilation

    Duration of mechanical ventilation is defined as the total number of hours from the initiation of invasive or non-invasive ventilation until the last successful extubation

    Time frame: From the initiation of mechanical ventilation until ICU discharge (up to 30 days).

  19. Requirement for left ventricular assist device implantation

    Requirement for left ventricular assist device implantation is defined as the need for implantation of a left ventricular assist device as bridge-to-transplant or destination therapy in patients with cardiogenic shock or end-stage heart failure who fail to maintain adequate end-organ perfusion despite optimized medical therapy.

    Time frame: From the end of iCDC infusion through study completion (up to 30 days).

  20. Duration of left ventricular assist device use

    Duration of left ventricular assist device use is defined as the total time from completion of device implantation until device removal, patient death, or the study cutoff date, whichever occurs first.

    Time frame: From left ventricular assist device implantation through study completion (up to 30 days).

  21. Simplified Acute Physiology Score II

    The Simplified Acute Physiology Score II (SAPS II) is a validated severity-of-disease scoring system used to assess the physiological status of critically ill patients. The score ranges from 0 to 163, with higher scores indicating greater disease severity and a worse prognosis. SAPS II will be calculated based on the worst physiological values recorded during each 24-hour period.

    Time frame: Daily from ICU admission through ICU discharge (up to 30 days).

  22. time to recovery from cardiogenic shock

    Time to recovery from cardiogenic shock is defined as the duration from the end of the single study drug infusion to the achievement of predefined criteria for hemodynamic stability and improvement in end-organ perfusion.

    Time frame: From the end of iCDC infusion to recovery from cardiogenic shock, assessed continuously until ICU discharge (up to 30 days).

  23. length of stay at the intensive care unit

    Length of stay in the ICU is defined as the total time from ICU admission until ICU discharge.

    Time frame: From ICU admission until ICU discharge (up to 30 days).

  24. Length of hospital stay;

    Total hospital length of stay is defined as the total calendar days from patient admission registration until final discharge or death, whichever occurs first.

    Time frame: From hospital admission until hospital discharge or death (up to 30 days).

  25. Left ventricular ejection fraction (LVEF)

    The difference of LVEF from baseline. LVEF will be assessed by echo.

    Time frame: 1 month after injection

  26. SCAI Shock Classification

    The SCAI shock classification is a standardized, five-stage system (from A to E) used to categorize the severity of cardiogenic shock based on clinical, hemodynamic, and biomarker criteria.

    Time frame: 3 days、7 days、14 days after injection

  27. assessment of heart failure symptom

    The difference of heart failure symptom, which will be assessed by NYHA grading and KCCQ score.

    Time frame: 1 month after injection

  28. Incidence of major adverse cardiovascular events (MACE)

    Incidence of Cardiac death, readmission due to heart failure.

    Time frame: 1 month after injection

  29. incidence of adverse events

    Incidence of adverse events of heart, nerve system, mental system, digestive system and immune system.

    Time frame: From the end of the drug infusion through study completion,up to 30 days.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 2, 2026
StartEst.
Jan 20, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Feb 28, 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07380659
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Jan 20, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Jiamin Li, MD
Contact
21818216@zju.edu.cn
86-18868112006
Xinyang Hu, PhD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion